Citigroup
OREX

Citigroup’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Citigroup’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-37,580
Closed -$48K – 7876
2017
Q4 		$48K Sell
37,580
-1,700
-4% -$2.77K ﹤0.01% 6222
2017
Q3 		$83K Sell
39,280
-11,300
-22% -$27.6K ﹤0.01% 5705
2017
Q2 		$147K Sell
50,580
-64,400
-56% -$193K ﹤0.01% 5039
2017
Q1 		$396K Buy
114,980
+106,760
+1,299% +$421K ﹤0.01% 4068
2016
Q4 		$14K Buy
8,220
+3,700
+82% +$8.7K ﹤0.01% 6664
2016
Q3 		$15K Buy
4,520
+3,680
+438% +$13.9K ﹤0.01% 6376
2016
Q2 		$4K Sell
840
-70
-8% -$316 ﹤0.01% 6853
2016
Q1 		$5K Sell
910
-110
-11% -$1.43K ﹤0.01% 7048
2015
Q4 		$18K Sell
1,020
-630
-38% -$15K ﹤0.01% 6551
2015
Q3 		$35K Buy
1,650
+810
+96% +$27.8K ﹤0.01% 5677
2015
Q2 		$42K Buy
+840
New +$50.2K ﹤0.01% 5659

Other funds holding OREX

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup's OREX Position: Q2 2018 in Review

Citigroup sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 39,243 shares — an estimated $8K sold.

Citigroup first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $4.02M in Q2 2013. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

  • Citigroup reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Citigroup sold 39,243 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $8K.
  • Citigroup first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
  • Citigroup's Orexigen Therapeutics, Inc. position peaked at $4.02M in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Citigroup's 13F filing for Q2 2018, filed 10 Aug 2018.